Currently, OPS202 is evaluated in Phase I/II clinical trials and is based on a new next generation antagonistic somatostatin analog with improved receptor binding to sst2. The company
As part of the deal, Aduro will receive a $30m up-front payment and is also eligible to receive significant development, regulatory and commercialization milestone payments up to a
As part of the development, Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, while Immune Design will provide its preclinical trivalent vaccine product candidate
Under the settlement agreement, the company will pay the amount in a series of tranches through August 2015. The litigation is related to how the company has historically
The new agreements were based on the existing strategic partnership, which includes an oncology research program and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute.
Lymphoseek (technetium Tc 99m tilmanocept) is now indicated for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with
The research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the
The acquisition is part of an ongoing collaboration and option agreement signed by the two companies in November 2012. As part of the acquisition, MorphoSys now has lanthipeptide
Ofev is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue and these capsules will be available to patients within
Esbriet is an oral medicine and is believed to interfere with the production of transforming growth factor (TGF) beta, a small protein in the body involved in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.